Introduction: Outcome for glioma (GBM) remains dismal despite advances in therapeutic interventions including chemotherapy, radiotherapy and surgical resection. The overall survival benefit observed with immunotherapies in cancers such as melanoma and prostate cancer has fuelled research into evaluating immunotherapies for GBM. Areas covered: Preclinical studies have brought a wealth of information for improving the prognosis of GBM and multiple clinical studies are evaluating a wide array of immunotherapies for GBM patients. This review highlights advances in the development of immunotherapeutic approaches. We discuss the strategies and outcomes of active and passive immunotherapies for GBM including vaccination strategies, gene therapy, c...
Purpose of reviewThis review seeks to inform oncology clinicians and researchers about the developme...
Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15 months when...
Purpose of reviewThis review seeks to inform oncology clinicians and researchers about the developme...
There is a large unmet need for effective therapeutic approaches for glioma, the most malignant brai...
Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality treatment with su...
Glioblastoma (GBM) is a lethal primary brain tumor. Despite extensive effort in basic, translational...
Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor. Every year ~22,...
Glioblastoma is the most frequent and the most aggressive brain tumor. It is notoriously resistant t...
Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor. Despi...
Glioblastoma (GBM) is an aggressive brain tumour, associated with extremely poor prognosis and altho...
Glioblastoma (GBM) is an aggressive brain tumour, associated with extremely poor prognosis and altho...
Glioblastoma (GBM) is an aggressive brain tumour, associated with extremely poor prognosis and altho...
Glioblastoma (GBM), a WHO grade IV brain tumor, is an aggressive tumor with poor prognosis; even wit...
Purpose of reviewThis review seeks to inform oncology clinicians and researchers about the developme...
PURPOSE OF REVIEW Immunotherapy is an emerging treatment strategy against various cancer types incl...
Purpose of reviewThis review seeks to inform oncology clinicians and researchers about the developme...
Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15 months when...
Purpose of reviewThis review seeks to inform oncology clinicians and researchers about the developme...
There is a large unmet need for effective therapeutic approaches for glioma, the most malignant brai...
Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality treatment with su...
Glioblastoma (GBM) is a lethal primary brain tumor. Despite extensive effort in basic, translational...
Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor. Every year ~22,...
Glioblastoma is the most frequent and the most aggressive brain tumor. It is notoriously resistant t...
Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor. Despi...
Glioblastoma (GBM) is an aggressive brain tumour, associated with extremely poor prognosis and altho...
Glioblastoma (GBM) is an aggressive brain tumour, associated with extremely poor prognosis and altho...
Glioblastoma (GBM) is an aggressive brain tumour, associated with extremely poor prognosis and altho...
Glioblastoma (GBM), a WHO grade IV brain tumor, is an aggressive tumor with poor prognosis; even wit...
Purpose of reviewThis review seeks to inform oncology clinicians and researchers about the developme...
PURPOSE OF REVIEW Immunotherapy is an emerging treatment strategy against various cancer types incl...
Purpose of reviewThis review seeks to inform oncology clinicians and researchers about the developme...
Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15 months when...
Purpose of reviewThis review seeks to inform oncology clinicians and researchers about the developme...